In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From Sanofi

Coronavirus Update: Pfizer/BioNTech Commit 500m Doses For US Donations

The US obtained access to doses that it will donate to low- and low-middle-income countries, Merck & Co. is lining up government purchases of its Phase III drug, and Ocugen will submit a BLA in the US rather than pursue an EUA for Bharat's vaccine. Plus progress and setbacks for COVID-19 therapeutics. 

Coronavirus COVID-19 Vaccines

BIO 2021 Notebook: Looking Past The Pandemic

News and views from day one of the BIO Digital annual meeting include debate about when FDA will go back to the offices, industry's role in pandemic-related policy discussions and how to prepare for the next pandemic. 

Coronavirus COVID-19 FDA

BIO 2021 Notebook: Looking Past The Pandemic

News and views from day one of the BIO Digital annual meeting include debate about when FDA will go back to the offices, industry's role in pandemic-related policy discussions and how to prepare for the next pandemic. 

Coronavirus COVID-19 FDA

Terns Says Phase IIa Data Show Superior NASH Safety Profile In FXR Class

TERN-101 showed a superior safety and tolerability profile for lipid levels and pruritis compared to other FXR agonists in a mid-stage study. Terns is now looking to a NASH combo study with its THR beta agonist.

Clinical Trials Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
    • Vaccines
  • Other Names / Subsidiaries
    • Ablynx N.V.
    • Acambis PLC
    • Bioverativ Inc. (True North Therapeutics, Inc.)
    • BiPar Sciences Inc.
    • BMP Sunstone Corporation
    • Canderm Pharma Inc.
    • Chattem, Inc.
    • Connaught Laboratories Ltd.
    • Fisons Ltd.
    • Fovea Pharmaceuticals, SA
    • Genfar S.A.
    • Genzyme Corporation
    • Groupe Sanofi
    • Hoechst Marion Roussel
    • Pluromed
    • Principia Biopharma Inc. Protein Sciences Corporation
    • Rhone-Poulenc Rorer
    • Sanofi-Aventis
    • Sanofi-aventis Groupe
    • Sanofi Pasteur MSD
    • Shantha
    • Synthorx, Inc. (THOR)
    • TargeGen, Inc.
    • Thunder Acquisition
    • Tidal Therapeutics, Avigen Inc., Kiadis Pharma N.V., Celmed BioSciences, Inc.
    • Kiadis Pharma B.V.
UsernamePublicRestriction

Register